Outcome of Board Meeting held on Thursday, 13th August, 2026

Corp. Off.:- 201, “The Summit Business Bay” Behind Guru Nanak Petrol Pump, Off Andheri Kurla Road, Andheri (E), Mumbai - 400 093 (India) Ph. : +91 22 69073100 13th August 2026 BSE Limited National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai-400001 Bandra (E), Mumbai-400051 Scrip Code: 533543 Symbol: BROOKS Sub: Outcome of Board Meeting held on Thursday, 13th August 2026. Dear Sir/Madam, Pursuant to provisions of Regulations 30 and 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e., on Thursday, 13th August 2026 inter alia, considered, approved and taken on record the following: 1. Unaudited Financial Results along with the Limited Review Report thereon for the quarter ended on 30th June, 2026. Extract of the Unaudited Financial Results along with Limited Review Report is enclosed herewith. The Board Meeting commenced at 4:00 P.M and concluded at 6:00 P.M. The above information will also be available on the Company’s website www.brookslabs.net. We request you to kindly take the same on record. Thanking You, Yours faithfully, For BROOKS LABORATORIES LIMITED Krutika Rane Company Secretary and Compliance Officer Membership no: 66310 Encl.: As Stated Regd. Off & Works : Village Kishanpura, Baddi Nalagarh Road, Baddi (H.P.) - 174101 (India) Tele Fax .: 01795 236939 (CIN NO: L24232HP2002PLC000267), E-mail : investors@brookslabs.net, Website: www.brookslabs.net Brooks Laboratories Limited Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101 CIN NO: L24232HP2002PLC000267 E-mail : investors@brookslabs.net | Website: www.brookslabs.net Statements of Unaudited Financial Results for the quarter ended 30th June 2026 (Rs. In Lakhs) Particulars Standalone Consolidated Quarter Ended Year Ended Quarter Ended Year Ended 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 Unaudited Audited Unaudited Audited Unaudited Audited Unaudited Audited 1Income Revenue from operations 2,296.08 2,020.95 2,551.19 8,573.84 2,296.08 2,020.95 2,551.19 8,573.84 Other Income 17.67 43.83 21.70 117.05 17.67 43.83 21.70 117.05 Total income 2,313.75 2,064.78 2,572.89 8,690.89 2,313.75 2,064.78 2,572.89 8,690.89 2Expenses (a) Cost of materials consumed 1,368.02 1,181.30 1,361.62 4,961.22 1,368.02 1,181.30 1,361.62 4,961.22 (b) Purchase of Stock in Trade 14.18 3.20 240.76 225.07 14.18 3.20 240.76 225.07 (c) Change in inventories of finished goods, work-in-progress and stock-in-trade ( 114.01) 57.39 ( 13.13) ( 84.10) ( 114.01) 57.39 ( 13.13) ( 84.10) (d) Employees benefits expenses 421.28 384.95 366.86 1,516.21 421.28 384.95 366.86 1,516.21 (e) Finance Costs 20.55 8.92 30.14 83.53 20.55 8.92 30.14 83.53 (f) Depreciation and amortization expenses 41.53 41.27 39.19 158.99 41.53 41.27 39.19 158.99 (g) Other expenses 420.34 326.32 282.39 1,249.47 420.34 326.32 282.39 1,249.47 Total Expenses 2,171.89 2,003.35 2,307.83 8,110.39 2,171.89 2,003.35 2,307.83 8,110.39 3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax 141.86 61.43 265.06 580.50 141.86 61.43 265.06 580.50 4Share of Profit / (Loss) from Jointly controlled entities and associates - - - ( 320.55) 90.87 693.42 1,877.85 Profit/(Loss) before Exceptional item and tax 141.86 61.43 265.06 580.50 ( 178.69) 152.30 958.48 2,458.35 5Exceptional items - - - - - - - - 6 Profit/(Loss) from ordinary activities before tax 141.86 61.43 265.06 580.50 ( 178.69) 152.30 958.48 2,458.35 7Tax Expense: Deferred Tax Liability / (Assets)(Refer note 6) - - - - - - - - MAT credit reversal - - - - - - - - Tax of earlier years - - - - - - - - 8Net Profit/(loss) after tax 141.86 61.43 265.06 580.50 ( 178.69) 152.30 958.48 2,458.35 9Other Comprehensive Income Items That will not be reclassified into Profit or loss Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax) - ( 3.07) - ( 3.07) - ( 3.07) - ( 3.07) 10Total Comprehensive income for the period 141.86 58.36 265.06 577.43 ( 178.69) 149.23 958.48 2,455.28 Net Profit attributable to Owners of equity - - - - ( 178.69) 152.30 958.48 2,458.35 Non Controlling Interest - - - - - - - - Other Comprehensive Income attributable to : Owners of equity - - - - - ( 3.07) - ( 3.07) Non Controlling Interest - - - - - - - - Total Comprehensive Income attributable to Owners of Equity - - - - ( 178.69) 149.23 958.48 2,455.28 Non Controlling Interest - - - - - - - 11Paid-up equity share capital (Face Value of Rs. 10 each) 2,945.72 2,945.72 2,945.72 2,945.72 2,945.72 2,945.72 2,945.72 2,945.72 12Reserves excluding Revaluation Reserves 9,138.68 9,319.99 13Earnings per share (of Rs. 10/- each) (not annualized) (a) Basic 0.48 0.21 0.90 1.97 ( 0.61) 0.52 3.25 8.35 (b) Diluted 0.48 0.21 0.90 1.97 ( 0.61) 0.52 3.25 8.35 Notes: 1 The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on August 13, 2026 2 The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevent rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016 3 Brooks Steriscience Limited, a jointly controlled entity, recorded revenue from operations of Rs. 1,751.30 lakhs for the quarter ended 30 June 2026, resulting in a loss after tax of Rs. 654.18 lakhs. Accordingly, the Company’s share of the loss after tax of the jointly controlled entity for the quarter ended 30 June 2026 amounting to Rs. 320.55 lakhs has been recognised and reported above. 4 The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures". 5 In the absence of reasonable certainty of future taxable profit, The Holding Company has not recognized deferred tax asset on its business losses/depreciation in accordance with Ind As 12 " Income taxes". 6 TheCompanyoperatesthroughtworeportablebusinesssegmentsinaccordancewithIndAS108–OperatingSegments,namelyTradingandManufacturing.Tradingcomprisesprincipal-to-principaltradingactivities,whileManufacturingincludes the Company’s own manufacturing operations and loan-licensing business. 7 ThenumbersforquarterendedMarch31,2026arethebalancingnumbersbetweenauditednumbersinrespectofthefullfinancialyearendedMarch31,2026andthepublishedreviewedyeartodatenumbersuptoandfortheninemonthsperiod ended December 31, 2025 8 Prior period figures have been regrouped and reclassified where necessary. For and on behalf of the Board Place : Baddi Bhushan Singh Rana Date : 13/08/2026 Din : 10289384 Whole time Director Brooks Laboratories Limited Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101 CIN NO: L24232HP2002PLC000267 E-mail : investors@brookslabs.net | Website: www.brookslabs.net Segment-wise Revenue, Results, Assets and Liabilities (Rs. In Lakhs) Particulars Standalone Consolidated Quarter Ended Year Ended Quarter Ended Year Ended 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 Unaudited Audited Unaudited Audited Unaudited Audited Unaudited Audited 1Segment Revenue a) Trading 18.53 23.22 36.19 286.58 18.53 23.22 36.19 286.58 b) Manufacturing 2,277.55 1,997.73 2,515.00 8,287.26 2,277.55 1,997.73 2,515.00 8,287.26 2,296.08 2,020.95 2,551.19 8,573.84 2,296.08 2,020.95 2,551.19 8,573.84 Less: Inter segment Revenue - - - - - - - - 2 ,296.08 2 ,020.95 2 ,551.19 8 ,573.84 2 ,296.08 2 ,020.95 2 ,551.19 8 ,573.84 Add: Unallocated - - - - - - - - Total revenue from operations 2 ,296.08 2 ,020.95 2 ,551.19 8 ,573.84 2 , [Showing first 8,000 characters — download PDF for full document]